Fate Therapeutics, Inc. (FATE)
1.28
-0.06
(-4.48%)
USD |
NASDAQ |
Nov 13, 16:00
1.275
0.00 (0.00%)
After-Hours: 19:59
Fate Therapeutics Net Income (Quarterly) : -30.69M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -30.69M |
| June 30, 2026 | -30.16M |
| March 31, 2026 | -31.21M |
| December 31, 2025 | -32.37M |
| September 30, 2025 | -32.25M |
| June 30, 2025 | -34.07M |
| March 31, 2025 | -37.62M |
| December 31, 2024 | -52.15M |
| September 30, 2024 | -47.68M |
| June 30, 2024 | -38.43M |
| March 31, 2024 | -48.00M |
| December 31, 2023 | -44.12M |
| September 30, 2023 | -45.17M |
| June 30, 2023 | -52.76M |
| March 31, 2023 | -18.88M |
| December 31, 2022 | -56.36M |
| September 30, 2022 | -83.56M |
| June 30, 2022 | -76.10M |
| March 31, 2022 | -65.69M |
| December 31, 2021 | -68.62M |
| September 30, 2021 | -43.31M |
| June 30, 2021 | -55.13M |
| March 31, 2021 | -45.09M |
| December 31, 2020 | -53.11M |
| September 30, 2020 | -58.68M |
| Date | Value |
|---|---|
| June 30, 2020 | -28.07M |
| March 31, 2020 | -33.52M |
| December 31, 2019 | -28.30M |
| September 30, 2019 | -26.61M |
| June 30, 2019 | -23.48M |
| March 31, 2019 | -19.76M |
| December 31, 2018 | -16.03M |
| September 30, 2018 | -16.78M |
| June 30, 2018 | -19.65M |
| March 31, 2018 | -14.14M |
| December 31, 2017 | -12.50M |
| September 30, 2017 | -10.68M |
| June 30, 2017 | -9.645M |
| March 31, 2017 | -10.13M |
| December 31, 2016 | -7.94M |
| September 30, 2016 | -8.737M |
| June 30, 2016 | -8.408M |
| March 31, 2016 | -8.377M |
| December 31, 2015 | -7.446M |
| September 30, 2015 | -6.886M |
| June 30, 2015 | -7.779M |
| March 31, 2015 | -7.881M |
| December 31, 2014 | -6.233M |
| September 30, 2014 | -6.603M |
| June 30, 2014 | -6.067M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AVITA Medical, Inc. | -6.222M |
| Agenus, Inc. | 1.567M |
| Amgen, Inc. | 3.864B |
| Anika Therapeutics, Inc. | -0.311M |
| BioCryst Pharmaceuticals, Inc. | 37.92M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 30.69M |
| EPS Diluted (Quarterly) | -0.2482 |
| Enterprise Value | 90.93M |
| Earnings Yield | -80.48% |
| Normalized Earnings Yield | -80.31 |